|
Cytarabine (Ara-C) Clinical Trials
5 actively recruiting trials across 2 locations
▲ +1 trial since August 2026
Also known as: Ara-C, Cytosar-U, Tarabine PFS, cytosine arabinoside (ara-C)
Pipeline
Early 1: 1Phase 2: 2Phase 3: 2
Top Sponsors
- Kura Oncology, Inc.1
- King Edward Medical University1
- First Affiliated Hospital of Zhejiang University1
- Beijing 302 Hospital1
- Baylor College of Medicine1
Indications
- Cancer5
- Acute Myeloid Leukemia2
- Acute T Lymphpblastic Leukemia/Lymphoma1
- Pediatric AML1
- DLBCL - Diffuse Large B Cell Lymphoma1
Other3 trials
Gilbert, Arizona1 trial
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Banner MD Anderson Cancer Center
Phase 3
Houston, Texas1 trial
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Texas Children's Cancer and Hematology Center
Early 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.